Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.340
-0.265 (-16.51%)
At close: Nov 12, 2026, 4:00 PM EST
1.280
-0.060 (-4.48%)
After-hours: Nov 12, 2026, 7:59 PM EST

Fate Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.756.6513.6363.5396.355.85
Revenue Growth
-33.45%-51.24%-78.55%-34.03%72.44%77.66%
Gross Profit
-87.15-85.25-104.9-93.65-224.15-159.67
Operating Income
-130-146.6-195.54-190.51-308.39-216.99
Net Income
-124.43-136.32-186.26-160.93-281.72-212.15
Earnings Per Share
-1.03-1.15-1.64-1.64-2.91-2.24
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
139.13203.66279.07315.18436.23615.91
Total Debt
74.4977.8585.27103.54109.34114.82
Net Cash (Debt)
64.64125.81193.8211.64326.89501.09
Net Cash Growth
-52.53%-35.09%-8.43%-35.26%-34.77%29.95%
Net Cash Per Share
0.531.061.702.153.385.29

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-105.46-106.08-122.87-132.26-248.21-162.87
Capital Expenditures
-1.51-5.95-0.73-6.15-35.57-50.7
Free Cash Flow
-106.97-112.04-123.6-138.42-283.77-213.57
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----147.41%-232.77%-285.92%
Operating Margin
-2736.88%-2205.90%-1434.52%-299.86%-320.24%-388.56%
Pretax Margin
-2619.64%-2051.08%-1366.46%-253.30%-292.55%-379.89%
Profit Margin
-2619.64%-2051.08%-1366.46%-253.30%-292.55%-379.89%
FCF Margin
-2252.08%-1685.78%-906.79%-217.87%-294.68%-382.43%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
33.6817.0613.795.8010.18100.05